Molecular imaging refers to visualizing, characterizing, and measuring biological processes at the molecular and cellular levels. Molecular imaging aids in visualization of physiological and biochemical processes that occur inside living systems. The technique is useful for disease diagnosis, drug discovery, drug development, and treatment monitoring. Techniques like positron emission tomography (PET) and single-photon emission computed tomography (SPECT) play a vital role.

The global Molecular Imaging Market is estimated to be valued at US$ 4786.94 Mn in 2023 and is expected to exhibit a CAGR of 5.2% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
The increasing incidence and prevalence of chronic diseases such as cancer and cardiovascular diseases has accelerated the demand for molecular imaging techniques for disease diagnosis. PET and SPECT scans help doctors diagnose and track disease progression by detecting areas of abnormal radioactivity concentration in tissues and organs. These techniques enable visualization of biological functions at the cellular and sub-cellular level in a non-invasive manner. The current trends suggest these molecular imaging modalities will continue witnessing wide adoption for disease diagnosis, thus driving the growth of the molecular imaging market over the forecast period.

Segment Analysis
The global molecular imaging market is segmented by product into small molecules and biologicals. The small molecules segment dominates the global market currently owing to widespread application of small molecule tracers like fluorodeoxyglucose (FDG) in positron emission tomography (PET) imaging procedures. Small molecule tracers have high detection sensitivity and allow visualization of various physiological and pathological processes at the molecular and cellular level.

Key Takeaways
The Global Molecular Imaging Market Size is expected to witness high growth over the forecast period aided by growing cancer burden and increasing healthcare spending. The global Molecular Imaging Market is estimated to be valued at US$ 4786.94 Mn in 2023 and is expected to exhibit a CAGR of 5.2% over the forecast period 2023 to 2030.

North America dominates currently due to availability of advanced diagnostic technologies and robust reimbursement framework in countries like US and Canada. Asia Pacific shows greatest potential for future expansion supported by large patient pools and improving access to healthcare in China and India.

Key players operating in the molecular imaging market include BASF SE, AkzoNobel N.V., Henkel AG & Co.KGaA, Solvay SA, Huntsman Corporation, Eastman Chemical Company, Lonza Group Limited, Procter & Gamble Co., Croda International Plc., The Dow Chemical Company, Betco Corporation, Sealed Air Corporation and Ecolab Inc. Leading companies are investing increasingly in R&D to develop advanced radiotracers and imaging agents for diagnosis and treatment monitoring in oncology and cardiology.

Get more insights on this topic:
https://www.zupyak.com/p/3968823/t/the-global-molecular-imaging-market-growth-accelerated-by-rising-demand-for-disease-diagnosis